Evaluating the Immunopathogenesis of Diabetes After Acute Pancreatitis in the Diabetes RElated to Acute Pancreatitis and Its Mechanisms Study: From the Type 1 Diabetes in Acute Pancreatitis Consortium
- PMID: 36206462
- PMCID: PMC9555855
- DOI: 10.1097/MPA.0000000000002076
Evaluating the Immunopathogenesis of Diabetes After Acute Pancreatitis in the Diabetes RElated to Acute Pancreatitis and Its Mechanisms Study: From the Type 1 Diabetes in Acute Pancreatitis Consortium
Abstract
The association between acute pancreatitis (AP) and diabetes mellitus (DM) has long been established, with the initial descriptions of AP patients presenting with DM after a bout of AP published in the 1940s and 50s. However, the potential mechanisms involved, particularly those components related to the immune system, have not been well defined. The Diabetes RElated to Acute pancreatitis and its Mechanisms (DREAM) study is a multicenter clinical study designed to understand the frequency and phenotype of DM developing after AP. This article describes one objective of the DREAM study: to determine the immunologic mechanisms of DM after AP, including the contribution of β-cell autoimmunity. This component of the study will assess the presence of islet autoimmunity, as well as the magnitude and kinetics of the innate and adaptive immune response at enrollment and during longitudinal follow-up after 1 or more episodes of AP. Finally, DREAM will evaluate the relationship between immune features, DM development, and pancreatitis etiology and severity.
Copyright © 2022 Written work prepared by employees of the Federal Government as part of their official duties is, under the U.S. Copyright Act, a “work of the United States Government” for which copyright protection under Title 17 of the United States Code is not available. As such, copyright does not extend to the contributions of employees of the Federal Government.
Conflict of interest statement
J.A.H. consults for aTyr Pharma. F.G.S.T. has received consulting fees from Sanofi, Eli Lilly, and AstraZeneca and research support from Dompé. G.I.P. has <5% equity with Ariel Precision Medicine, has consulted with Nestle, and receives research funds from Abbvie. M.D.B. receives research support from Viacyte and Dexcom and has participated on an advisory board with Insulet. C.S. participates on an advisory board for Vertex Pharmaceuticals. The rest of the authors declare no conflict of interest.
References
-
- Bonifacio E, Lampasona V, Genovese S, et al. Identification of protein tyrosine phosphatase-like IA2 (islet cell antigen 512) as the insulin-dependent diabetes-related 37/40K autoantigen and a target of islet-cell antibodies. J Immunol. 1995;155:5419–5426. - PubMed
-
- Shamoon M, Deng Y, Chen YQ, et al. Therapeutic implications of innate immune system in acute pancreatitis. Expert Opin Ther Targets. 2016;20:73–87. - PubMed
-
- Liang T, Liu TF, Xue DB, et al. Different cell death modes of pancreatic acinar cells on macrophage activation in rats. Chin Med J (Engl). 2008;121:1920–1924. - PubMed
-
- Demols A, Le Moine O, Desalle F, et al. CD4(+)T cells play an important role in acute experimental pancreatitis in mice. Gastroenterology. 2000;118:582–590. - PubMed
Publication types
MeSH terms
Grants and funding
- U01 DK127403/DK/NIDDK NIH HHS/United States
- U01 DK127392/DK/NIDDK NIH HHS/United States
- U01 DK127367/DK/NIDDK NIH HHS/United States
- U01 DK127395/DK/NIDDK NIH HHS/United States
- U01 DK108314/DK/NIDDK NIH HHS/United States
- U01 DK127388/DK/NIDDK NIH HHS/United States
- U01 DK127377/DK/NIDDK NIH HHS/United States
- U01 DK127382/DK/NIDDK NIH HHS/United States
- U01 DK127400/DK/NIDDK NIH HHS/United States
- U01 DK127378/DK/NIDDK NIH HHS/United States
- U01 DK127404/DK/NIDDK NIH HHS/United States
- U01 DK127384/DK/NIDDK NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
